Novo Nordisk has lowered its full-year 2025 sales and operating profit forecasts due to weaker-than-expected growth in its key obesity and diabetes drugs, the Danish drugmaker announced Tuesday.
The company employs more than 400 people at its West Lebanon, NH, location, where it celebrated its 10thanniversary in the Granite State last year. The facility makes pharmaceutical ingredients for two ailments specific to Hemophilia A and growth hormone disorder.
For the first six months of 2025, Novo Nordisk reported an 18% increase in sales and a 29% rise in operating profit, both at constant exchange rates. The growth was buoyed by prior-year gross-to-net sales adjustments, including a DKK 3 billion adjustment tied to the 340B provision in Q2.
Novo Nordisk in West Lebanon, pictured here, employs more than 400 people in New Hampshire. (Courtesy photo)
Operating profit also benefited from a prior-year impairment charge and was partially offset by the costs associated with its acquisition of three Catalent manufacturing facilities.
Despite strong results in the first half, Novo Nordisk revised its full-year guidance. The company now expects 2025 sales to grow 8-14%, down from the previous 13-21% range. Operating profit is now forecast to grow 10-16%, compared to 16-24% previously.
The downgrade is attributed largely to reduced expectations for Wegovy and Ozempic sales in the U.S., and slower uptake in select international obesity markets, the company said.
For Wegovy in the U.S., the revised outlook stems from ongoing market competition, persistent use of compounded GLP-1 products, and slower-than-expected market expansion.
“Despite the expiry of the FDA grace period for mass compounding on 22 May 2025, Novo Nordisk market research shows that unsafe and unlawful mass compounding has continued,” the company said. “Novo Nordisk is deeply concerned that, without aggressive intervention by federal and state regulators and law enforcement, patients will continue to be exposed to the significant risks posed by knockoff ‘semaglutide’ drugs.”
To counter challenges in the cash market, the company launched NovoCare Pharmacy and telehealth collaborations, generating about 31,000 weekly Wegovy prescriptions. However, penetration in the insured market has also been slower than projected.
Ozempic faces increasing U.S. competition, impacting expectations, though Novo Nordisk continues to invest in marketing and product updates.
Full first-half results will be published on Aug. 6.
The vote is a culmination of months of organizing by nurses, fueled by concerns about chronic staffing shortages, burnout and corresponding worries about nurse and patient safety as a result.
After two years of extensive evaluation of various affiliation models, the Littleton Regional Healthcare (LRH) Board of Trustees has chosen Dartmouth Health (DH) as its preferred partner. LRH and DH have signed a letter of intent, which serves as the next step toward LRH joining the Dartmouth Health system.
Educational institutions and hospitals are taking steps to help alleviate New Hampshire’s primary care doctor shortage by trying to expand the pipeline of doctors to help replace those who are leaving.
It’s getting harder for patients to find a doctor as wait times and barriers to access grow
Meet Samii, the mannequin who is bedridden in the AI Simulation Lab, one of the drawing cards to the new $32 million home of the Jean School of Nursing and Health Sciences at Saint Anselm College.
Two for-profit methadone clinics in Derry and Salem are under investigation as part of a statewide initiative looking into unnecessary barriers patients might face when seeking treatment for opioid addiction.
Bedford Ambulatory Surgical Center (BASC) has added a powerful new tool to its orthopedic suite: endoscopic spine surgery.
Lebanon company’s breast cancer locator won the nh tech alliance’s product of the year in 2021
Novo Nordisk has lowered its full-year 2025 sales and operating profit forecasts due to weaker-than-expected growth in its key obesity and diabetes drugs, the Danish drugmaker announced Tuesday. Novo Nordisk employs more than 400 people at its West Lebanon, NH, location.
